Sanofi: The Early Bird in Avian Flu
The French pharma is speeding its promising vaccine into production. That's good news for global health, but maybe not for the company's profits
By Carol Matlack
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.